NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individual therapies, and current and forecasted market ...

Tango Therapeutics (NASDAQ:TNGX) is preparing to move further into late-stage development for its PRMT5 inhibitor ...

Investing.com -- Personalis Inc (NASDAQ:PSNL) stock jumped 9.3% Tuesday after the precision oncology company announced ...

Results showed the combination reduced the risk of death by 24% compared with chemotherapy alone, extending median OS to 18.2 months. Along with improved progression-free survival, the approval ...

Personalis, Inc. , a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company's NeXT Personal molecular residual disease (MRD) test for surveillance of ...

The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical ...

Medicare will reimburse the company’s NeXT Personal molecular residual disease (MRD) test when used to monitor patients with ...

Personalis shares rose after the company received Medicare coverage for its NeXT Personal molecular residual disease test for surveillance of patients with Stage I to III non-small cell lung cancer.

Improved Pharma, a leader in pharmaceutical research and solid-state chemistry, is pleased to announce a significant upgrade to its analytical capabilities with the installation of a fully automated ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...

After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030 ...